Bioaegis: plasma gelsolin (PGSN), an abundant, circulating protein modulates inflammation while also enhancing host defenses by stimulating the uptake and killing of pathogens. Clinical studies have…
Active Definitive Contract Awarded Last action
- Contract number
- 75A50123C00067
- Awardee
-
Bioaegis Therapeutics Inc. UEI G2AZAC2PG7X3
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $20,000,000
Award facts
- Contract value 100% obligated
- $20,000,000.00 Current and potential, with all options
- Completion date 79% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 100 offers Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Morristown, NJ 07960, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $20,000,000 |
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a $20 million definitive contract to Bioaegis Therapeutics Inc. for recombinant human plasma gelsolin (rhu-PGSN) development and clinical research on September 21, 2023, under a firm fixed price structure with no set-aside.
The procurement covers plasma gelsolin, a circulating protein that modulates inflammation and enhances host defenses by stimulating pathogen uptake and killing. Clinical studies have demonstrated that plasma gelsolin is depleted in severe acute respiratory distress syndrome (ARDS), positioning rhu-PGSN as a therapeutic candidate. Place of performance is Morristown, NJ. Performance extends through August 31, 2027.
In FY2024, the contract invoiced $8.7 million across 29.3 FTEs and 60,831 contractor hours, yielding a derived government-paid hourly rate of $143.12. Bioaegis self-performed all reported labor with no subcontractor engagement.
Description
Bioaegis: plasma gelsolin (PGSN), an abundant, circulating protein modulates inflammation while also enhancing host defenses by stimulating the uptake and killing of pathogens. Clinical studies have consistently shown PGSN is depleted in severe I
Quick answers
Who was awarded contract 75A50123C00067?
75A50123C00067 was awarded to Bioaegis Therapeutics Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 21, 2023.
How much is contract 75A50123C00067 worth?
The government has obligated $20,000,000 on 75A50123C00067.
Was contract 75A50123C00067 competed?
The extent of competition for 75A50123C00067 was full and open competition. The government received 100 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award